Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Hansa Biopharma AB ( (SE:HNSA) ) is now available.
Hansa Biopharma announced a directed share issue of 17 million ordinary shares to facilitate their trading on Nasdaq Stockholm, with trading expected to commence around October 6, 2025. This move is part of Hansa’s strategic efforts to enhance its market presence and operational capabilities, potentially impacting its industry positioning and stakeholder interests.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company based in Lund, Sweden, focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation, with products like imlifidase and HNSA-5487.
Average Trading Volume: 534,308
Technical Sentiment Signal: Buy
Current Market Cap: SEK3.62B
Find detailed analytics on HNSA stock on TipRanks’ Stock Analysis page.